Clopidogrel-induced hepatotoxicity after percutaneous coronary stenting

Hong Kong Medical Journal

Volumn 11, Issue 5, 2005, Pages 414-416

  Chau, T N ^a   Yim, K F ^b   Mok, N S ^b   Chan, W K ^a   Leung, V K S ^a   Leung, M F ^a   Lai, S T ^b  

^a UNITED CHRISTIAN HOSPITAL   (Hong Kong)

^b PRINCESS MARGARET HOSPITAL   (Hong Kong)

Author keywords

Adverse effects; Clopidogrel; Drug toxicity; Hepatitis

Indexed keywords

ADENOSINE DIPHOSPHATE RECEPTOR BLOCKING AGENT; CLOPIDOGREL; PANTOPRAZOLE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; AGED; CASE REPORT; CORONARY ARTERY DISEASE; CORONARY STENT; HEPATITIS; HUMAN; LIVER DISEASE; LIVER TOXICITY; MALE; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; SYMPTOMATOLOGY; THROMBOCYTE AGGREGATION INHIBITION;

AGED; COMBINED MODALITY THERAPY; CORONARY DISEASE; HEPATITIS, TOXIC; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; STENTS; TICLOPIDINE;

EID: 27144453648     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
2. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, Investigators FT. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-9.
3. Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3Suppl):576S-599S.
4. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-20.
5. Tsui PT, Lai ST, Leung WS, et al. Prolonged jaundice following percutaneous coronary intervention and ticlopidine therapy. Hong Kong Med J 2002;8:57-9.
6. Pierce CH, Houle JM, Dickinson JP, et al. Clopidogrel and drug metabolism: absence effect on hepatic enzymes in healthy volunteers. Semin Thromb Hemost 1999;25(Suppl):35S-39S.
7. Beltran-Robles M, Marquez Saavedra E, Sanchez-Munoz D, Romero-Gomez M. Hepatotoxicity induced by clopidogrel. J Hepatol 2004;40:560-2.
8. Ramos Ramos JC, Sanz Moreno J, Calvo Carrasco L, Garcia Diaz Jde D. Clopidogrel-induced hepatotoxicity [in Spanish]. Med Clin (Barc) 2003;120:156-7.
9. Duran Quintana JA, Jimenez Saenz M, Montero AR, Gutierrez MH. Clopidogrel probably induced hepatic toxicity [in Spanish]. Med Clin 2002;119:37.
10. Willens HJ. Clopidogrel-induced mixed hepatocellular and cholestatic liver injury. Am J Ther 2000;7:317-8.
11. Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997;26:664-9.
12. Trivier JM, Caron J, Mahieu M, Cambier N, Rose C. Fatal aplastic anaemia associated with clopidogrel. Lancet 2001; 357:446.
13. Cordes A, Vogt W, Maier KP. Pantoprazole-induced hepatitis [in German]. Dtsch Med Wochenschr 2003;128:611-4.
14. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003;31:53-9.
15. Zeolla MM, Carson JJ. Successful use of clopidogrel for cerebrovascular accident in a patient with suspected ticlopidine-induced hepatotoxicity. Ann Pharmacother 1999; 33:939-41.